Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
Autor: | Clifford J. Rosen, Angela M. Cheung, M. Hassan Murad, Dennis M. Black, Richard Eastell, Dolores M. Shoback |
---|---|
Rok vydání: | 2020 |
Předmět: |
Societies
Scientific medicine.medical_specialty Active Comparator Endocrinology Diabetes and Metabolism Clinical Biochemistry Osteoporosis Romosozumab Boxed warning 030209 endocrinology & metabolism Biochemistry 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Bone Density Internal medicine medicine Humans 030212 general & internal medicine Adverse effect Intensive care medicine Osteoporosis Postmenopausal business.industry Biochemistry (medical) Antibodies Monoclonal Guideline Prognosis medicine.disease Clinical trial chemistry Practice Guidelines as Topic Sclerostin Female business Osteoporotic Fractures |
Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 105:587-594 |
ISSN: | 1945-7197 0021-972X |
Popis: | Objective The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab. Conclusions We reviewed findings from the meta-analysis and primary clinical trials assessing the efficacy of romosozumab, a monoclonal antibody targeting sclerostin, for the prevention of fractures and concluded that this agent can be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture. The romosozumab label has a boxed warning, recommending careful consideration by the treating clinician as to cardiovascular risk profile in the individual woman who might receive this agent, since clinical trial data from an active comparator study show an imbalance in serious cardiovascular adverse events between romosozumab and alendronate. |
Databáze: | OpenAIRE |
Externí odkaz: |